Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-10), SenzaGen AB's 3-1 Month Momentum % is -5.08%.
The industry rank for SenzaGen AB's 3-1 Month Momentum % or its related term are showing as below:
FRA:26S's 3-1 Month Momentum % is ranked worse than 68.84% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.38
vs FRA:26S: -5.08
SenzaGen AB (FRA:26S) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
SenzaGen AB 3-1 Month Momentum % Related Terms
FRA:26S vs TMO, DHR, NTRA: 3-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, SenzaGen AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SenzaGen AB 3-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SenzaGen AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where SenzaGen AB's 3-1 Month Momentum % falls into.
SenzaGen AB (FRA:26S) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SenzaGen AB (FRA:26S) has a 3-1 Month Momentum % of -5.08% as of Sep. 10, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on SenzaGen AB and its competitors. According to the industry distribution chart, SenzaGen AB ranks #148 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 68.8%.
Is SenzaGen AB's 3-1 Month Momentum % too high?
SenzaGen AB's current 3-1 Month Momentum % is -5.08%. Based on the distribution chart, SenzaGen AB ranks #148 out of 215 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, SenzaGen AB has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does SenzaGen AB's 3-1 Month Momentum % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SenzaGen AB ranks #148 out of 215 companies for 3-1 Month Momentum %. This places SenzaGen AB in the lower half of its industry. The industry median 3-1 Month Momentum % is 2.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Diagnostics & Research company?
The median 3-1 Month Momentum % among Medical Diagnostics & Research companies is 2.38, based on 215 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on SenzaGen AB and its competitors. For the Medical Diagnostics & Research industry, the median 3-1 Month Momentum % is 2.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SenzaGen AB's current 3-1 Month Momentum % is -5.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SenzaGen AB stock overvalued right now?
SenzaGen AB (FRA:26S) has a current 3-1 Month Momentum % of -5.08%. The stock's GF Value™ is €0.54, compared to a current price of €0.44 — trading 18.9% below its estimated fair value. The current 3-1 Month Momentum % is -5.08%. SenzaGen AB's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For SenzaGen AB (FRA:26S), the current 3-1 Month Momentum % is -5.08% as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SenzaGen AB (FRA:26S) Overvalued in 2026?
Based on GuruFocus' analysis, SenzaGen AB stock appears to be undervalued.
The current stock price of €0.44 is trading 18.9% below its estimated GF Value™ of €0.54.
Key valuation signals for FRA:26S:
3-1 Month Momentum %: -5.08%
GF Value™: €0.54 vs. price of €0.44 (18.9% below fair value)
No single metric tells the full story. See the FRA:26S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SenzaGen AB markets, sells, and performs in vitro testing using its Genomic Allergen Rapid Detection (GARD) platform through its laboratory and a network of contract research organizations. The company provides animal-free testing solutions for chemical compounds used in industries such as cosmetics, chemicals, pharmaceuticals, medical devices, and food and nutrition. Geographically, it operates in the Americas, EMEA, and APAC, with the majority of revenue from EMEA.
71GF Score
Get the complete analysis for FRA:26S
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:26S has been successfully added to your 
